CVALFCovalon Technologies Ltd.

About Covalon Technologies Ltd. (CVALF)

Covalon Technologies Ltd. (CVALF) is a Biotechnology company headquartered in Mississagua, ON, Canada whose shares trade over-the-counter on the OTCQX tier.

Covalon Technologies Ltd. is a research-driven developer, manufacturer, and marketer of patent-protected medical products that improve patient outcomes and save lives, specializing in advanced wound care, infection prevention, and surgical solutions. We leverage our proprietary medical technology platforms and expertise in two key ways: developing and marketing innovative medical solutions under the Covalon brand and collaborating with other medical companies to develop and commercialize products through licensing and development agreements.

Products and services

Covalon Technologies Ltd. is a research-driven developer, manufacturer, and marketer of patent-protected medical products that enhance patient outcomes and save lives in infection management, advanced wound care, and surgical solutions. We leverage our proprietary medical technology platforms and expertise in two key ways: developing and marketing innovative medical solutions under the Covalon brand, and partnering with other medical companies to develop and commercialize products through licensing and development agreements. Covalon currently has three proprietary platform technologies with the potential to be developed into a wide range of medical devices and products: (i) collagen matrix, (ii) antimicrobial silicone adhesive, and (iii) medical coating technology. These platforms are protected through a combination of patents, patent applications, proprietary manufacturing processes, trade secrets, trademarks, and brand assets.

CVALF key facts

Ticker symbol

CVALF

Market tier

OTCQX

Sector

Healthcare

Industry

Biotechnology

Headquarters

Mississagua, ON, Canada

Country of incorporation

CA

Year of incorporation

2004

Employees

73

Estimated market cap

$47.16M (as of Apr 15, 2025)

Shares outstanding

27,418,077

Reporting standard

International Reporting: TSX Venture Exchange

Audit status

Audited

Fiscal year end

9/30

Latest filing

Quarterly Report (Dec 31, 2024)

Covalon Technologies Ltd. leadership

• Brent Ashton — CEO
• Kathryn Martinovich — Interim CFO
• Kimberley Crooks — SVP, Ops.
• Val DiTizio — Chief Scientific Officer
• Accounts Payable — Other

Explore more: Biotechnology stocks · Healthcare sector · OTCQX stocks · OTC stocks starting with C